Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Apnimed, Inc.

NASDAQ: APMD · Life Sciences · 3 alerts · CIK 1745648

Share price
$16.28Close, Nov 16
Market cap
$678M
Shares outstanding
41.63MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Apnimed, Inc. filings on SEC EDGAR ↗

8:11 AM ET 10-Q
Financial Results

Apnimed Q3 2026 Results: Net Loss of $29.5M, Loss Widens

Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on its lead product candidate, Oxnimbi, which has completed Phase 3 clinical trials. The company reports significant operating losses since inception and anticipates requiring substantial additional funding to support its commercialization efforts and regulatory approval processes.

Key figure
Net loss $29.5M
8:05 AM ET 8-K
Financial Results

Apnimed Financial Results

Apnimed reported third quarter 2026 financial results, highlighting a cash position of $351.8 million following its upsized IPO in August. The company's NDA for AD109 (Oxnimbi) for the treatment of obstructive sleep apnea remains under FDA review with a PDUFA goal date of February 28, 2027.

“We are in a transformational period at Apnimed. With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story.”

Kevin Lind, Chief Executive Officer of Apnimed

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.